1	A	A	B-NP	DT	O	3	NMOD
2	large	large	I-NP	JJ	O	3	NMOD
3	outbreak	outbreak	I-NP	NN	O	0	ROOT
4	of	of	B-PP	IN	O	3	NMOD
5	Salmonella	Salmonella	B-NP	NNP	O	8	NMOD
6	Paratyphi	Paratyphi	I-NP	NNP	O	8	NMOD
7	A	A	I-NP	NNP	O	8	NMOD
8	infection	infection	I-NP	NN	O	4	PMOD
9	among	among	B-PP	IN	O	3	NMOD
10	israeli	israeli	B-NP	JJ	O	11	NMOD
11	travelers	traveler	I-NP	NNS	O	9	PMOD
12	to	to	B-PP	TO	O	3	NMOD
13	Nepal	Nepal	B-NP	NNP	O	12	PMOD
14	.	.	O	.	O	3	P

1	In	In	B-PP	IN	O	7	VMOD
2	Asia	Asia	B-NP	NNP	O	7	SUB
3	,	,	O	,	O	7	P
4	Salmonella	Salmonella	B-NP	NNP	O	6	NMOD
5	Paratyphi	Paratyphi	I-NP	NNP	O	6	NMOD
6	A	A	I-NP	NNP	O	7	SUB
7	is	be	B-VP	VBZ	O	14	VMOD
8	an	an	B-NP	DT	O	10	NMOD
9	emerging	emerge	I-NP	VBG	O	10	NMOD
10	infection	infection	I-NP	NN	O	7	PRD
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	VMOD
13	travelers	traveler	B-NP	NNS	O	14	SUB
14	are	be	B-VP	VBP	O	0	ROOT
15	increasingly	increasingly	B-ADVP	RB	O	14	VMOD
16	at	at	B-PP	IN	O	14	VMOD
17	risk	risk	B-NP	NN	O	16	PMOD
18	.	.	O	.	O	14	P

1	During	During	B-PP	IN	O	0	ROOT
2	October	October	B-NP	NNP	O	3	NMOD
3	2009-November	2009-November	I-NP	NNP	O	13	VMOD
4	2009	2009	I-NP	CD	O	3	NMOD
5	,	,	O	,	O	13	P
6	an	an	B-NP	DT	O	7	NMOD
7	outbreak	outbreak	I-NP	NN	O	13	SUB
8	in	in	B-PP	IN	O	7	NMOD
9	S.	S.	B-NP	NNP	O	12	NMOD
10	Paratyphi	Paratyphi	I-NP	NNP	O	12	NMOD
11	A	A	I-NP	NNP	O	12	NMOD
12	infection	infection	I-NP	NN	O	8	PMOD
13	was	be	B-VP	VBD	O	1	SBAR
14	noted	note	I-VP	VBN	O	13	VC
15	in	in	B-PP	IN	O	14	VMOD
16	Israeli	Israeli	B-NP	JJ	O	17	NMOD
17	travelers	traveler	I-NP	NNS	O	15	PMOD
18	returning	return	B-VP	VBG	O	17	NMOD
19	from	from	B-PP	IN	O	18	VMOD
20	Nepal	Nepal	B-NP	NNP	O	19	PMOD
21	.	.	O	.	O	1	P

1	An	An	B-NP	DT	O	3	NMOD
2	outbreak	outbreak	I-NP	JJ	O	3	NMOD
3	investigation	investigation	I-NP	NN	O	4	SUB
4	included	include	B-VP	VBD	O	0	ROOT
5	a	a	B-NP	DT	O	8	NMOD
6	standardized	standardized	I-NP	JJ	O	8	NMOD
7	exposure	exposure	I-NP	NN	O	8	NMOD
8	questionnaire	questionnaire	I-NP	NN	O	4	OBJ
9	admitted	admit	B-VP	VBN	O	8	NMOD
10	to	to	B-PP	TO	O	9	VMOD
11	all	all	B-NP	DT	O	12	NMOD
12	patients	patient	I-NP	NNS	O	16	NMOD
13	and	and	O	CC	O	16	NMOD
14	medical	medical	B-NP	JJ	O	16	NMOD
15	chart	chart	I-NP	NN	O	16	NMOD
16	abstraction	abstraction	I-NP	NN	O	10	PMOD
17	.	.	O	.	O	4	P

1	Isolates	Isolate	B-NP	NNS	O	2	SUB
2	were	be	B-VP	VBD	O	0	ROOT
3	tested	test	I-VP	VBN	O	2	VC
4	for	for	B-PP	IN	O	3	VMOD
5	antimicrobial	antimicrobial	B-NP	JJ	O	6	NMOD
6	susceptibility	susceptibility	I-NP	NN	O	10	NMOD
7	and	and	O	CC	O	10	NMOD
8	pulsed-field	pulsed-field	B-NP	JJ	O	10	NMOD
9	gel	gel	I-NP	NN	O	10	NMOD
10	electrophoresis	electrophoresis	I-NP	NN	O	4	PMOD
11	(	(	O	(	O	13	DEP
12	PFGE	PFGE	B-NP	NN	O	13	DEP
13	)	)	O	)	O	10	NMOD
14	.	.	O	.	O	2	P

1	During	During	B-PP	IN	O	0	ROOT
2	1	1	B-NP	CD	O	10	NMOD
3	October	October	I-NP	NNP	O	10	NMOD
4	2009-30	2009-30	I-NP	CD	O	10	NMOD
5	November	November	I-NP	NNP	O	10	NMOD
6	2009	2009	I-NP	CD	O	5	NMOD
7	,	,	I-NP	,	O	10	P
8	37	37	I-NP	CD	O	10	NMOD
9	Israeli	Israeli	I-NP	JJ	O	10	NMOD
10	travelers	traveler	I-NP	NNS	O	14	SUB
11	returning	return	B-VP	VBG	O	10	NMOD
12	from	from	B-PP	IN	O	11	VMOD
13	Nepal	Nepal	B-NP	NNP	O	12	PMOD
14	were	be	B-VP	VBD	O	1	SBAR
15	diagnosed	diagnose	I-VP	VBN	O	14	VC
16	with	with	B-PP	IN	O	15	VMOD
17	S.	S.	B-NP	NNP	O	20	NMOD
18	Paratyphi	Paratyphi	I-NP	NNP	O	20	NMOD
19	A	A	I-NP	NNP	O	20	NMOD
20	bacteremia	bacteremia	I-NP	NN	O	16	PMOD
21	.	.	O	.	O	1	P

1	All	All	B-NP	DT	O	4	NMOD
2	37	37	I-NP	CD	O	4	NMOD
3	case	case	I-NP	NN	O	4	NMOD
4	isolates	isolate	I-NP	NNS	O	5	SUB
5	had	have	B-VP	VBD	O	14	VMOD
6	an	an	B-NP	DT	O	8	NMOD
7	identical	identical	I-NP	JJ	O	8	NMOD
8	pattern	pattern	I-NP	NN	O	5	OBJ
9	on	on	B-PP	IN	O	5	VMOD
10	PFGE	PFGE	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	14	P
12	and	and	O	CC	O	14	VMOD
13	all	all	B-NP	DT	O	14	SUB
14	were	be	B-VP	VBD	O	0	ROOT
15	nalidixic	nalidixic	B-NP	JJ	O	16	AMOD
16	acid	acid	I-NP	NN	O	14	PRD
17	resistant	resistant	B-ADJP	JJ	O	16	AMOD
18	.	.	O	.	O	14	P

1	Only	Only	B-NP	RB	O	4	NMOD
2	1	1	I-NP	CD	O	4	NMOD
3	food	food	I-NP	NN	O	4	NMOD
4	venue	venue	I-NP	NN	O	5	SUB
5	was	be	B-VP	VBD	O	0	ROOT
6	frequented	frequent	I-VP	VBN	O	5	VC
7	by	by	B-PP	IN	O	6	VMOD
8	all	all	B-NP	PDT	O	11	NMOD
9	the	the	I-NP	DT	O	11	NMOD
10	outbreak	outbreak	I-NP	JJ	O	11	NMOD
11	cases	case	I-NP	NNS	O	7	PMOD
12	,	,	O	,	O	6	P
13	with	with	B-PP	IN	O	6	VMOD
14	the	the	B-NP	DT	O	16	NMOD
15	largest	large	I-NP	JJS	O	16	NMOD
16	number	number	I-NP	NN	O	13	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	exposures	exposure	B-NP	NNS	O	17	PMOD
19	occurring	occur	B-VP	VBG	O	18	NMOD
20	around	around	B-PP	IN	O	19	VMOD
21	the	the	B-NP	DT	O	24	NMOD
22	Jewish	Jewish	I-NP	NNP	O	24	NMOD
23	New	New	I-NP	NNP	O	24	NMOD
24	Year	Year	I-NP	NNP	O	20	PMOD
25	.	.	O	.	O	5	P

1	All	All	B-NP	DT	O	2	NMOD
2	patients	patient	I-NP	NNS	O	3	SUB
3	recovered	recover	B-VP	VBD	O	0	ROOT
4	without	without	B-PP	IN	O	3	VMOD
5	complications	complication	B-NP	NNS	O	4	PMOD
6	.	.	O	.	O	3	P

1	Time	Time	B-NP	NN	O	13	SUB
2	to	to	B-PP	TO	O	1	NMOD
3	defervescence	defervescence	B-NP	NN	O	2	PMOD
4	in	in	B-PP	IN	O	1	NMOD
5	17	17	B-NP	CD	O	6	NMOD
6	patients	patient	I-NP	NNS	O	4	PMOD
7	treated	treat	B-VP	VBN	O	6	NMOD
8	with	with	B-PP	IN	O	7	VMOD
9	ceftriaxone	ceftriaxone	B-NP	NN	O	12	NMOD
10	and	and	I-NP	CC	O	12	NMOD
11	azithromycin	azithromycin	I-NP	NN	O	12	NMOD
12	combination	combination	I-NP	NN	O	8	PMOD
13	was	be	B-VP	VBD	O	0	ROOT
14	3.2	3.2	B-NP	CD	O	15	NMOD
15	days	day	I-NP	NNS	O	13	PRD
16	(	(	O	(	O	19	DEP
17	±	±	B-NP	NN	O	19	DEP
18	1.7	1.7	I-NP	CD	O	17	NMOD
19	)	)	O	)	O	15	NMOD
20	,	,	O	,	O	13	P
21	whereas	whereas	O	IN	O	13	VMOD
22	in	in	B-PP	IN	O	34	VMOD
23	13	13	B-NP	CD	O	24	NMOD
24	cases	case	I-NP	NNS	O	22	PMOD
25	treated	treat	B-VP	VBN	O	24	NMOD
26	with	with	B-PP	IN	O	25	VMOD
27	ceftriaxone	ceftriaxone	B-NP	NN	O	28	NMOD
28	monotherapy	monotherapy	I-NP	NN	O	26	PMOD
29	,	,	O	,	O	34	P
30	the	the	B-NP	DT	O	31	NMOD
31	time	time	I-NP	NN	O	34	SUB
32	to	to	B-PP	TO	O	31	NMOD
33	defervescence	defervescence	B-NP	NN	O	32	PMOD
34	was	be	B-VP	VBD	O	21	SBAR
35	6.6	6.6	B-NP	CD	O	36	NMOD
36	days	day	I-NP	NNS	O	34	PRD
37	(	(	O	(	O	44	DEP
38	±	±	B-NP	NN	O	41	NMOD
39	1.8	1.8	I-NP	CD	O	38	NMOD
40	;	;	O	:	O	38	P
41	P	P	B-NP	NN	O	44	DEP
42	<	<	B-NP	JJR	O	41	NMOD
43	.001	.001	I-NP	CD	O	42	AMOD
44	)	)	O	)	O	36	NMOD
45	.	.	O	.	O	13	P

1	A	A	B-NP	DT	O	2	NMOD
2	point-source	point-source	I-NP	NN	O	9	NMOD
3	,	,	O	,	O	9	P
4	``	``	O	``	O	9	NMOD
5	Paratyphoid	Paratyphoid	B-NP	JJ	O	9	NMOD
6	Mary	Mary	I-NP	NNP	O	9	NMOD
7	''	''	I-NP	''	O	9	NMOD
8	-like	-like	I-NP	JJ	O	9	NMOD
9	outbreak	outbreak	I-NP	NN	O	10	SUB
10	was	be	B-VP	VBD	O	0	ROOT
11	identified	identify	I-VP	VBN	O	10	VC
12	among	among	B-PP	IN	O	11	VMOD
13	Israeli	Israeli	B-NP	JJ	O	14	NMOD
14	travelers	traveler	I-NP	NNS	O	12	PMOD
15	to	to	B-PP	TO	O	11	VMOD
16	Nepal	Nepal	B-NP	NNP	O	15	PMOD
17	.	.	O	.	O	10	P

1	Combination	Combination	B-NP	NN	O	3	NMOD
2	Ceftriaxone-Azithromycin	Ceftriaxone-Azithromycin	I-NP	NN	O	3	NMOD
3	therapy	therapy	I-NP	NN	O	4	SUB
4	may	may	B-VP	MD	O	0	ROOT
5	provide	provide	I-VP	VB	O	4	VC
6	a	a	B-NP	DT	O	8	NMOD
7	therapeutic	therapeutic	I-NP	JJ	O	8	NMOD
8	advantage	advantage	I-NP	NN	O	5	OBJ
9	over	over	B-PP	IN	O	8	NMOD
10	monotherapy	monotherapy	B-NP	NN	O	9	PMOD
11	,	,	O	,	O	4	P
12	and	and	O	CC	O	4	VMOD
13	merits	merit	B-VP	VBZ	O	4	VMOD
14	further	further	B-NP	JJ	O	16	NMOD
15	clinical	clinical	I-NP	JJ	O	16	NMOD
16	trials	trial	I-NP	NNS	O	13	OBJ
17	.	.	O	.	O	4	P

